Health Care Equipment & Services

Insider buying signals confidence: CEO Joel L & execs buy 100k+ CHEMED options at $512.64, reflecting strong growth prospects and alignment of interests.

CEO Kevin McNamara’s latest insider purchase of 36,693 CHEMED shares signals long‑term confidence in the company’s healthcare‑diversification strategy and suggests its stock may still be undervalued.

Insider sales by Penumbra’s President reveal a balanced buying trend amid a bullish run—signs of long‑term confidence, growth prospects, and strategic portfolio moves.

Investor insights: Doximity’s recent insider purchase shows disciplined liquidity management and steady confidence, highlighting its competitive edge in physician networking and digital health growth.

Medtronic insider sales: Marinaro sells 10,420 shares, CEO sells 50,000, reflecting routine portfolio shifts amid post‑MiniMed split focus.

Melissa B. Cummings’ recent PROGYNY insider sell‑trades show routine portfolio management, not distress—her continued stake signals confidence in the company’s growth and menopause‑focused benefits.

Veeva insider selling rises: Jonathan Faddis sells 5,600 shares at $300 as the stock nears a 52‑week high—investors learn the strategy and what it means for long‑term value.

Mark Hopman’s recent 775‑share sale at BETA Bionics hints at rising insider caution amid FDA scrutiny and market volatility—what does this mean for investors?

Claritev insider sale: Senior VP Tiffani Misencik sells 15,806 shares amid a 34% stock decline, but board expansion signals ongoing growth focus.

Explore how Tarheel Investors’ 4.75M stake in Integer Holdings signals confidence in its Armstrong merger, insider activity, and investor upside.